PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 403/12, 239/70, A61K 31/505

A1

(11) International Publication Number: WO 95/30673

(43) International Publication Date: 16 November 1995 (16.11.95)

(21) International Application Number: PCT/GB95/01016

(22) International Filing Date: 4 May 1995 (04.05.95)

(30) Priority Data:
9408936.4 5 May 1994 (05.05.94) GB

(71) Applicants *(for all designated States except US)*: BRITISH TECHNOLOGY GROUP LIMITED [GB/GB]; 101 Newington Causeway, London SE1 6BU (GB). ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: BAVETSIAS, Vassilios [GR/GB]; 3 Chiddingstone Close, Sutton, Surrey SM2 6NS (GB). BOYLE, Francis, Thomas [GB/GB]; Hinstock Mount, Astbury Lane Ends, Cangleton, Cheshire CW12 3AY (GB). HENNEQUIN, Laurent, François, André [FR/FR]; "Le Collegium", Apartement 4A, 29c, boulevard Saint-Marceau, F-51100 Reims Cédex (FR). MARRIOTT, Jonathan, Hugh [GB/GB]; 247 Brighton Road, Sutton, Surrey SM2 5ST (GB).

(74) Agent: STEPHENSON, Gerald, Frederick; Patents Dept., British Technology Group Limited, 101 Newington Causeway, London SE1 6BU (GB).

(81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.

(54) Title: ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING



(I)

(57) Abstract

Cyclopentaquinazoline of formula (I), wherein R^1 is hydrogen, amino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} hydroxyalkyl or C_{1-4} fluoroalkyl; wherein R^2 is hydrogen, C_{1-4} alkyl, C_{3-4} alkenyl, C_{3-4} alkynyl, C_{2-4} hydroxyalkyl, C_{2-4} halogenoalkyl or C_{1-4} cyanoalkyl; Ar^1 is phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, C_{1-4} alkyl and C_{1-4} alkoxy; and wherein R^3 is a group of the formula: $-A^1-Ar^2-A^2-Y^1$, in which A^1 is a bond between the α-carbon atom of the group $-CONHCH(CO_2H)-$ and Ar^2 or is a C_{1-2} alkylene group; Ar^2 is phenylene, tetrazoldiyl, tiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which in the case of phenylene may optionally bear one or two substituents on the ring selected from halogeno, nitro, C_{1-4} alkyl and C_{1-4} alkoxy; A^2 is a C_{1-3} alkylene or C_{2-3} alkenylene group; and a pharmaceutically acceptable salt or ester thereof are of therapeutic value particularly in the treatment of cancer.